Hereditary angioedema is a disorder that results in frequent attacks of pain and inflammation accompanied with the swelling of legs, intestinal tract, arms, face and airway tract. There are three types of hereditary angioedema, types I, II and III which are distinguished by the underlying causes and the levels of blood protein called C1 inhibitors. Phenotypic expression in hereditary angioedema varies widely even among family members, the frequency and severity of attacks are unpredictable giving an expression that similar symptoms arises in all types. Type III was initially thought to be prevalent only in women but incidences have occurred in males in the same affected families.
For the purpose of this study, the global hereditary angioedema market is studied in terms of drug classes, pipeline drugs and geography. The drug classes studied in the report include C1 esterase inhibitors (Berinert, Haegarda, Cinryze and Ruconest), kallikrein inhibitors (Kalbitor), selective bradykinin B2 receptor antagonist (Firazyr) and others. The current pipeline drugs for this market include Phase III drug DX-2930 and phase II drug BCX-7353.
The geographic segmentation of the global hereditary angioedema market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global hereditary angioedema market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global hereditary angioedema market. The key players profiled in this report are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd.
North America was observed to be the largest market for hereditary angioedema in the base year 2021. According to the US Hereditary Angioedema Association, in 2016, about 3,904 people suffered with hereditary angioedema. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of hereditary angioedema, presence of pharmaceutical giants such as BioCryst Pharmaceuticals, Inc., CSL Behring and existence of developed research and healthcare institutions. The market growth in Europe is mainly attributed to the rising prevalence of genetic rare diseases, increasing demand for novel drugs for the treatment of hereditary angioedema and affordable reimbursement scenario for the treatment of genetic rare diseases. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2022-2030. Factors that are anticipated to propel the market growth are the increasing disposable income and supportive regulatory environment for hereditary angioedema products. Moreover, factors such as developing health infrastructure, expansion by pharmaceutical giants in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of hereditary angioedema market in Latin America, and Middle East and Africa in the near future.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
For the purpose of this study, the global hereditary angioedema market is studied in terms of drug classes, pipeline drugs and geography. The drug classes studied in the report include C1 esterase inhibitors (Berinert, Haegarda, Cinryze and Ruconest), kallikrein inhibitors (Kalbitor), selective bradykinin B2 receptor antagonist (Firazyr) and others. The current pipeline drugs for this market include Phase III drug DX-2930 and phase II drug BCX-7353.
The geographic segmentation of the global hereditary angioedema market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global hereditary angioedema market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global hereditary angioedema market. The key players profiled in this report are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd.
Drug class Analysis
The hereditary angioedema market is driven by factors such as increasing expenditure in pharmaceutical and biotechnology R&D focusing on genetic rare diseases, rising public awareness and alliances between pharmaceutical giants and research institutes. In addition, increasing number of diagnostic centers and growing physician awareness regarding disease etiology will propel the market penetration of hereditary angioedema drugs. In 2016, C1 esterase inhibitors segment held the largest market share chiefly due to factors such as recent FDA approval of Berinert and Haegarda. Technological advancement in the drug delivery for e.g. Haegarda is the only medication available as a subcutaneous treatment option for hereditary angioedema. Kallikrien inhibitors will be the fastest growing segment throughout the forecast period 2017-2025. Factors contributing to the growth of this segment are increasing incidences in patients with angioedema anaphylactic shock and promising product pipeline consisting of selective kallikrien inhibitors and plasma kallikrien inhibitors resulting in immediate relief due to faster onset of action. The major players in hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, Teva Pharmaceutical Industries Ltd.North America was observed to be the largest market for hereditary angioedema in the base year 2021. According to the US Hereditary Angioedema Association, in 2016, about 3,904 people suffered with hereditary angioedema. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of hereditary angioedema, presence of pharmaceutical giants such as BioCryst Pharmaceuticals, Inc., CSL Behring and existence of developed research and healthcare institutions. The market growth in Europe is mainly attributed to the rising prevalence of genetic rare diseases, increasing demand for novel drugs for the treatment of hereditary angioedema and affordable reimbursement scenario for the treatment of genetic rare diseases. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2022-2030. Factors that are anticipated to propel the market growth are the increasing disposable income and supportive regulatory environment for hereditary angioedema products. Moreover, factors such as developing health infrastructure, expansion by pharmaceutical giants in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of hereditary angioedema market in Latin America, and Middle East and Africa in the near future.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hereditary Angioedema market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Hereditary Angioedema market and their expected impact during the forecast period.
Market Segmentation
Drug Class
- C1 Esterase Inhibitors
- Berinert
- Haegarda
- Cinryze
- Ruconest
- Kallikrien Inhibitor
- Kalbitor
- Selective Bradykinin B2 Receptor Antagonist
- Firazyr
- Others
Product Drugs
- Phase III Drug
- DX-2930
- Phase II Drug (Qualitative Information)
- BCX-7353
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Hereditary Angioedema market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Hereditary Angioedema market?
- Which is the largest regional market for Hereditary Angioedema market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Hereditary Angioedema market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Hereditary Angioedema market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Hereditary Angioedema Market
2.2. Global Hereditary Angioedema Market, By Drug Class, 2021 (US$ Million)
2.3. Global Hereditary Angioedema Market, By Product Drugs, 2021 (US$ Million)
2.4. Global Hereditary Angioedema Market, By Geography, 2021 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2021
3. Hereditary Angioedema Market: Competitive Analysis
3.1. Market Positioning of Key Hereditary Angioedema Market Vendors
3.2. Strategies Adopted by Hereditary Angioedema Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Hereditary Angioedema Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Hereditary Angioedema Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. C1 Esterase Inhibitors
5.3.1.1. Berinert
5.3.1.2. Haegarda
5.3.1.3. Cinryze
5.3.1.4. Ruconest
5.3.2. Kallikrien Inhibitor
5.3.2.1. Kalbitor
5.3.3. Selective Bradykinin B2 Receptor Antagonist
5.3.3.1. Firazyr
5.3.4. Others
6. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Phase III Drug
6.3.1.1. DX-2930
6.3.2. Phase II Drug (Qualitative Information)
6.3.2.1. BCX-7353
7. North America Hereditary Angioedema Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
7.3. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
7.4.Hereditary Angioedema Market: By Region, 2020-2030, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
7.4.1.1.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
7.4.1.2.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
7.4.1.3.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
8. UK and European Union Hereditary Angioedema Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
8.3. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
8.4.Hereditary Angioedema Market: By Region, 2020-2030, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
8.4.1.1.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
8.4.1.2.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
8.4.1.3.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
8.4.1.4.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
8.4.1.5. France
8.4.1.5.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
8.4.1.5.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
8.4.1.6.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
9. Asia Pacific Hereditary Angioedema Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
9.3. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
9.4.Hereditary Angioedema Market: By Region, 2020-2030, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
9.4.1.1.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
9.4.1.2.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
9.4.1.3. India
9.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
9.4.1.3.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
9.4.1.4.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
9.4.1.5.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
9.4.1.6.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
10. Latin America Hereditary Angioedema Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
10.3. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
10.4.Hereditary Angioedema Market: By Region, 2020-2030, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
10.4.1.1.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
10.4.1.2.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
10.4.1.3.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
11. Middle East and Africa Hereditary Angioedema Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
11.3. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
11.4.Hereditary Angioedema Market: By Region, 2020-2030, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
11.4.1.1.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
11.4.1.2.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2020-2030, USD (Million)
11.4.1.3.1. Hereditary Angioedema Market: By Product Drugs, 2020-2030, USD (Million)
12. Company Profile
12.1. BioCryst Pharmaceuticals, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Cipla, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. CSL Behring Ltd.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Ionis Pharmaceuticals, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. iBio, Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Merck & Co., Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Pharming Group NV
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Sanofi N.V.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Shire plc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Teva Pharmaceutical Industries, Ltd.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Other Notable Players
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
List of Figures
Figure 1 Global Hereditary Angioedema Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Hereditary Angioedema Market: Quality Assurance
Figure 5 Global Hereditary Angioedema Market, By Drug Class, 2021
Figure 6 Global Hereditary Angioedema Market, By Product Drugs, 2021
Figure 7 Global Hereditary Angioedema Market, By Geography, 2021
Figure 8 Market Geographical Opportunity Matrix - Global Hereditary Angioedema Market, 2021
Figure 9 Market Positioning of Key Hereditary Angioedema Market Players, 2021
Figure 10 Global Hereditary Angioedema Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 11 Global Hereditary Angioedema Market, By Drug Class, 2021 Vs 2030, %
Figure 12 Global Hereditary Angioedema Market, By Product Drugs, 2021 Vs 2030, %
Figure 13 U.S. Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 14 Canada Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 15 Rest of North America Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 16 UK Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 17 Germany Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 18 Spain Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 19 Italy Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 20 France Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 21 Rest of Europe Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 22 China Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 23 Japan Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 24 India Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 25 Australia Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 26 South Korea Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 27 Rest of Asia Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 28 Brazil Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 29 Mexico Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 30 Rest of Latin America Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 31 GCC Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 32 Africa Hereditary Angioedema Market (US$ Million), 2020 - 2030
Figure 33 Rest of Middle East and Africa Hereditary Angioedema Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 2 Global Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 3 Global Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 4 Global Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 5 Global Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 6 Global Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 7 Global Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 8 North America Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 9 North America Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 10 North America Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 11 North America Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 12 North America Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 13 North America Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 14 North America Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 15 U.S. Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 16 U.S. Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 17 U.S. Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 18 U.S. Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 19 U.S. Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 20 U.S. Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 21 U.S. Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 22 Canada Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 23 Canada Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 24 Canada Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 25 Canada Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 26 Canada Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 27 Canada Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 28 Canada Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 29 Rest of North America Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 30 Rest of North America Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 31 Rest of North America Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 32 Rest of North America Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 33 Rest of North America Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 34 Rest of North America Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 35 Rest of North America Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 36 UK and European Union Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 37 UK and European Union Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 38 UK and European Union Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 39 UK and European Union Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 40 UK and European Union Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 41 UK and European Union Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 42 UK and European Union Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 43 UK Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 44 UK Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 45 UK Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 46 UK Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 47 UK Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 48 UK Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 49 UK Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 50 Germany Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 51 Germany Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 52 Germany Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 53 Germany Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 54 Germany Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 55 Germany Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 56 Germany Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 57 Spain Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 58 Spain Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 59 Spain Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 60 Spain Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 61 Spain Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 62 Spain Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 63 Spain Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 64 Italy Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 65 Italy Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 66 Italy Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 67 Italy Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 68 Italy Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 69 Italy Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 70 Italy Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 71 France Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 72 France Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 73 France Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 74 France Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 75 France Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 76 France Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 77 France Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 78 Rest of Europe Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 79 Rest of Europe Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 80 Rest of Europe Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 81 Rest of Europe Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 82 Rest of Europe Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 83 Rest of Europe Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 84 Rest of Europe Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 85 Asia Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 86 Asia Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 87 Asia Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 88 Asia Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 89 Asia Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 90 Asia Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 91 Asia Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 92 China Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 93 China Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 94 China Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 95 China Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 96 China Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 97 China Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 98 China Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 99 Japan Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 100 Japan Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 101 Japan Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 102 Japan Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 103 Japan Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 104 Japan Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 105 Japan Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 106 India Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 107 India Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 108 India Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 109 India Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 110 India Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 111 India Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 112 India Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 113 Australia Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 114 Australia Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 115 Australia Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 116 Australia Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 117 Australia Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 118 Australia Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 119 Australia Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 120 South Korea Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 121 South Korea Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 122 South Korea Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 123 South Korea Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 124 South Korea Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 125 South Korea Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 126 South Korea Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 127 Latin America Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 128 Latin America Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 129 Latin America Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 130 Latin America Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 131 Latin America Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 132 Latin America Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 133 Latin America Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 134 Brazil Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 135 Brazil Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 136 Brazil Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 137 Brazil Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 138 Brazil Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 139 Brazil Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 140 Brazil Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 141 Mexico Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 142 Mexico Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 143 Mexico Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 144 Mexico Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 145 Mexico Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 146 Mexico Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 147 Mexico Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 148 Rest of Latin America Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 149 Rest of Latin America Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 150 Rest of Latin America Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 151 Rest of Latin America Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 152 Rest of Latin America Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 153 Rest of Latin America Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 154 Rest of Latin America Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 155 Middle East and Africa Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 156 Middle East and Africa Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 157 Middle East and Africa Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 158 Middle East and Africa Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 159 Middle East and Africa Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 160 Middle East and Africa Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 161 Middle East and Africa Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 162 GCC Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 163 GCC Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 164 GCC Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 165 GCC Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 166 GCC Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 167 GCC Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 168 GCC Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 169 Africa Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 170 Africa Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 171 Africa Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 172 Africa Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 173 Africa Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 174 Africa Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 175 Africa Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Table 176 Rest of Middle East and Africa Hereditary Angioedema Market By Drug Class, 2020-2030, USD (Million)
Table 177 Rest of Middle East and Africa Hereditary Angioedema Market By C1 Esterase Inhibitors, 2020-2030, USD (Million)
Table 178 Rest of Middle East and Africa Hereditary Angioedema Market By Kallikrien Inhibitor, 2020-2030, USD (Million)
Table 179 Rest of Middle East and Africa Hereditary Angioedema Market By Selective Bradykinin B2 Receptor Antagonist, 2020-2030, USD (Million)
Table 180 Rest of Middle East and Africa Hereditary Angioedema Market By Product Drugs, 2020-2030, USD (Million)
Table 181 Rest of Middle East and Africa Hereditary Angioedema Market By Phase III Drug, 2020-2030, USD (Million)
Table 182 Rest of Middle East and Africa Hereditary Angioedema Market By Phase II Drug (Qualitative Information), 2020-2030, USD (Million)
Companies Mentioned
- BioCryst Pharmaceuticals Inc.
- Cipla Inc.
- CSL Behring Ltd.
- Ionis Pharmaceuticals Inc.
- iBio Inc.
- Merck & Co. Inc.
- Pharming Group NV
- Sanofi N.V.
- Shire plc
- Teva Pharmaceutical Industries Ltd.
